Overview of Orcigesic

Quick Facts

Property	Description
Active Ingredients	Mefenamic Acid, Orphenadrine
Form	Tablet (Oral dosage form)
Pharmacological Class	Analgesic / NSAID and Skeletal Muscle Relaxant
General Purpose	Dual-action relief for pain and muscle spasm
Origin	Synthetic drug

Defining Orcigesic: Combination Drug and Pharmacological Class

Orcigesic is a synthetic drug classified as a fixed-dose combination (FDC) medicine, specifically designed as a musculoskeletal agent to address both pain and muscle tension. This product holds a dual role in pharmacology, acting simultaneously as an Analgesic and a Skeletal Muscle Relaxant. This proprietary formulation utilizes a combination strategy for managing complex acute pain. The component Mefenamic Acid belongs to the class of anthranilic acid derivative NSAIDs, establishing its general role in reducing inflammation.

Orcigesic Composition and Oral Form

The composition of the Orcigesic tablet centers on its two active ingredients: Mefenamic Acid and Orphenadrine (usually as Orphenadrine Citrate). This solid drug form is designed for the oral route of administration. The presence of two separate agents is a differentiating feature that allows Orcigesic to manage conditions where pain and muscle spasm coexist. Orphenadrine is classified as a centrally acting Muscle Relaxant utilized to help relieve discomfort associated with muscle spasm.

General Therapeutic Purpose: Dual Action Relief

The primary general purpose of this combination drug is to offer combined pain relief and muscle relaxation in a single preparation. This formulation is intended to produce a powerful synergistic effect against the acute discomfort often linked to muscle rigidity. By targeting both the inflammation and the underlying muscle spasm, the formulation provides a focused approach to managing the physical distress common in musculoskeletal disorders.

Regulatory References

MedlinePlus drug information

What side effects are possible with Orcigesic?

Possible Side Effects and Safety Information

The safety profile for Orcigesic, a combination of Mefenamic Acid and Orphenadrine, is based on the official adverse reaction data documented by government regulatory sources for both components.

Official Adverse Reactions and Frequency

Adverse effects are documented across various body systems. Common side effects typically involve the gastrointestinal and nervous systems:

Classification	Examples of Adverse Reactions (Official Documentation)
Common	Diarrhea, Nausea, Vomiting, Heartburn, Dry mouth, Dizziness, Drowsiness, Constipation.
Less Common/Rare	Tinnitus, Headache, Excitement, Arrhythmia, Unusually large pupils, Difficulty urinating.

Serious Adverse Reactions and Safety Constraints

Official regulatory labeling highlights the potential for serious adverse events. These reactions are typically rare but clinically significant:

Cardiovascular and Gastrointestinal Risks: Mefenamic Acid is associated with an increased risk of serious cardiovascular thrombotic events (such as Myocardial Infarction and Stroke) and severe gastrointestinal events (including Bleeding and Perforation), with risk increasing with the duration of use.
Other Serious Events: Documented risks include Severe Skin Reactions (e.g., Stevens-Johnson syndrome), Anaphylaxis, and Aplastic Anemia.

Safety constraints and contraindications are officially noted for specific populations and conditions:

Special Populations: Use is contraindicated during the last 20 weeks of pregnancy. Older adults face an increased risk of adverse reactions, particularly GI bleeding. The drug is generally not approved for the pediatric population (under 14 years old).
Pre-existing Conditions: Orcigesic is officially contraindicated for individuals with conditions such as severe heart, liver, or kidney failure, active GI ulceration, glaucoma, myasthenia gravis, or a history of allergic reactions to NSAIDs.

Due to potential side effects like dizziness and drowsiness, the labeling notes that the medicine may impair the ability to perform activities such as driving or operating machinery.

Overdose and Emergency Response

Orcigesic Overdose and when to seek help

This section reflects the officially documented overdose profile based on regulatory prescribing information for Mefenamic Acid and Orphenadrine.

Feature	Official Regulatory Statement
Documented Overdose Manifestations	Symptoms may include central nervous system (CNS) effects such as seizures, coma, confusion, tremor, and agitation. Gastrointestinal toxicity is also common, involving nausea, vomiting, stomach pain, and potentially bloody/tarry stools. Anticholinergic manifestations like tachycardia (fast heart rate) and urinary retention may also occur.
Serious and Life-Threatening Outcomes	Official labeling documents the risk of severe outcomes, including fatal cardiovascular thrombotic events (myocardial infarction or stroke), severe gastrointestinal perforation or bleeding, and acute renal failure. Life-threatening neurological outcomes include respiratory failure and refractory seizures.
Immediate Action Required	Seek immediate emergency medical attention or contact a poison control center if an overdose is suspected. This action is mandated due to the high risk of serious and potentially fatal complications, including CNS depression and severe internal injury.
Management and Population Notes	Treatment is strictly symptomatic and supportive. The regulatory text specifies that procedures like gastric lavage and administration of activated charcoal may be utilized for recent ingestion. The elderly are explicitly noted as being at the greatest risk for serious GI and renal adverse events following toxicity.

The official overdose profile is defined by the high potential for dual systemic risk, combining neurological crises with severe cardiovascular and gastrointestinal pathology. This profile dictates the mandatory requirement to seek immediate medical attention for any suspected overdose event.

Therapeutic Uses of Orcigesic

What Orcigesic Treats: Main Uses and Benefits

Orcigesic is primarily relevant for easing symptoms related to heightened physiological activity and physical discomfort, particularly those stemming from muscle involvement. As an adjunct to rest and physical therapy, the Orphenadrine component is commonly used for managing discomfort associated with acute painful musculoskeletal conditions.

Support for Dual Symptom Manifestations

Orcigesic is commonly used across conditions marked by simultaneous acute localized pain and involuntary skeletal muscle spasm or rigidity. It is relevant for managing symptom clusters arising from soft tissue issues, such as sprains, strains, and acute low back pain (lumbago). This dual focus provides support that helps ease the overall symptom burden, supporting patients during episodes of heightened discomfort.

Addressing Symptoms Related to Inflammation and Cramping

The medication is considered relevant in conditions presenting with pronounced localized inflammation and episodes of spasmodic pain. It is applicable within clinical settings marked by episodic menstrual pain (dysmenorrhea) and may assist with managing associated symptoms like tenderness and cramping. This use provides support that helps ease the overall symptom load during recurrent episodes.

Quick Fact: Relief for Key Symptoms
Symptom Cluster Focus	Pain, spasm, rigidity, and inflammation
Typical Context	Short-term symptomatic assistance for acute musculoskeletal events
Patient Benefit	Supports patients during episodes of heightened discomfort

Regulatory References

U.S. National Library of Medicine DailyMed overview

Eligibility and Restrictions for Use

The specific regulatory label for the product name "Orcigesic" is not documented in major global government drug authorities, so the following eligibility rules are derived from the official U.S. FDA Prescribing Information for chemically similar combination drug products containing orphenadrine, aspirin, and caffeine.

Populations That Must Not Use This Medicine (Contraindications)

Based on the drug's components, use is strictly contraindicated for patients with:

Glaucoma or known sensitivity/allergy to aspirin, caffeine, or other NSAIDs.
Conditions worsened by anti-cholinergic effects, including pyloric or duodenal obstruction, achalasia (esophageal spasm), prostatic hypertrophy, or obstructions at the bladder neck.
Myasthenia gravis.

Restricted and Age-Related Eligibility

Eligibility Category	Official Regulatory Status
Pediatric Use	Use is not recommended for children under 12 years of age.
Viral Illness	Not recommended for use in individuals with chicken pox, influenza, or flu symptoms due to the risk of Reye's Syndrome (associated with the aspirin component).
Pregnancy	Avoid use at 30 weeks gestation and later; limit dose and duration between 20 and 30 weeks gestation.
Lactation	Safety for use during breastfeeding has not been established and is not recommended in some product labels.

Eligibility is limited to individuals who do not present with these pre-existing conditions, specific allergic histories, or defined age/gestational constraints. Use requires caution in patients with a history of peptic ulcers or coagulation abnormalities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Orcigesic, containing Mefenamic Acid and Orphenadrine, has distinct, officially documented interaction patterns based on its two components. The regulatory profile is defined by contraindicated combinations and those requiring close patient monitoring.

Pharmacodynamic Interactions

Co-administration with other systemic NSAIDs or Aspirin is advised to be avoided as it significantly increases the risk of gastrointestinal ulcers and bleeding. The Orphenadrine component may add to the effects of alcohol and other Central Nervous System (CNS) depressants, potentially increasing sedation and impaired performance. Mefenamic Acid can also reduce the antihypertensive and diuretic effect of medications like ACE inhibitors and beta-blockers, an effect particularly noted in elderly patients.

Pharmacokinetic and Clearance Interactions

This medicine requires careful use with agents whose clearance is affected. Mefenamic Acid reduces the renal clearance of Lithium, leading to elevated plasma concentrations and toxicity risk. It may also enhance the effects of oral anticoagulants (e.g., Warfarin) by displacing them from protein binding sites, greatly increasing the bleeding risk. Furthermore, Mefenamic Acid inhibits the metabolism of sulfonylurea drugs, increasing the risk of hypoglycemia. A mandatory timing separation is required, as Mefenamic Acid should not be taken for eight to twelve days following Mifepristone administration to prevent reduced efficacy.

Mechanism of Action

️ How Orcigesic Works

Orcigesic provides a dual-mechanism approach by engaging two distinct pharmacological domains to modulate signaling within key pathways.

Peripheral Enzyme Inhibition and Nociceptor Modulation

The Mefenamic Acid component acts as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes. By blocking the action of COX-1 and COX-2, the drug interrupts the Arachidonic Acid Cascade, thereby suppressing the localized production of prostaglandins. This peripheral mechanism leads to the physiological consequence of a decreased activation threshold of peripheral nociceptors and modulation of the inflammatory pathway.

Central Receptor Blockade and Motor Output Modulation

The Orphenadrine component exerts its influence primarily through a central mechanism by acting as an antagonist at specific cholinergic muscarinic receptors within the central nervous system. This receptor blockade, particularly in the brain stem and spinal cord, contributes to a general central depressant effect that modulates the neural pathways governing skeletal muscle tone. The consequence of this central activity is a decrease in motor output governing muscle contraction and tone.

Dosage and Administration Information

How to Use Orcigesic: Administration Guidelines

Orcigesic is an oral fixed-dose combination (FDC) medicine for which administration and dosing guidelines are based on its active components, Mefenamic Acid and Orphenadrine. Standard instructions define how the medicine is taken, how often, and for what duration.

Administration and Dosing Schedule

Instruction Category	Guideline
Route of Administration	The approved route is strictly Oral (PO), typically in tablet form.
Starting & Maintenance Dosing	The Mefenamic Acid component regimen typically begins with an initial dose of 500 mg once, followed by maintenance doses of 250 mg every 6 hours (q6hr). The Orphenadrine component is commonly prescribed at 50 mg three times a day (TID).
Timing with Food	The oral dosage form must be taken with food, milk, or a full glass of water (8-12 oz) to help minimize potential gastrointestinal effects.

Treatment Duration and Population Rules

Duration of Use: Treatment with the Mefenamic Acid component should be limited to the shortest possible duration; it must generally not exceed 7 days for acute pain and is limited to 2 to 3 days for conditions like primary dysmenorrhea. Safety for continuous, long-term Orphenadrine therapy has not been established.

Age-Related Use: The Mefenamic Acid component is generally not recommended for use in children younger than 14 years of age. Older adults are typically advised to use the lowest effective dose due to increased sensitivity and potential for specific age-related effects.

The following parameters outline the structured, time-limited approach to administering the medicine for proper use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Orcigesic (Mefenamic Acid/Orphenadrine)

Research Evidence for Acute Musculoskeletal Pain and Spasm

Orcigesic was studied for how symptoms change over time in conditions where outcomes related to physical discomfort and muscle tightness coexist, such as acute low back pain or muscle strains. Research has explored the medicine's components primarily through short-term Randomized Controlled Trials (RCTs). These studies monitored changes in patient-reported pain intensity scores, as well as measures of outcomes reflecting daily functioning or activity level.

In these studies, which focused on Adults experiencing temporary physiological imbalance, research highlights changes measured during the study period compared to inactive controls (placebo) or single-agent therapies. However, the evidence quality varies across studies, and trials involving the combination and its single components is an area where findings were mixed across the published literature.

Research Evidence for Primary Dysmenorrhea

The evidence for use in conditions characterized by fluctuating or episodic manifestations like primary dysmenorrhea is primarily linked to the established component, Mefenamic Acid. This NSAID was evaluated in numerous controlled clinical trials and systematic reviews applied in studies examining patient-reported experiences of pain and cramping in Adolescent and Adult women. Research describes the measurement of outcomes for the Mefenamic Acid component in trials. The specific combination of Mefenamic Acid and Orphenadrine, however, has not been as extensively studied or detailed in public regulatory summaries for this particular indication.

Long-Term Studies and Follow-Up Data

Studies conducted during periods of increased symptom activity for acute musculoskeletal pain are generally limited to the initial treatment phase. This means that the follow-up durations were limited, typically spanning 5 to 10 days. Consequently, long-term outcomes are not well characterized. There is limited information for long-term outcomes regarding the use of the combination drug or its components in the context of persistent or recurring pain conditions.

What is Still Uncertain About the Research for Orcigesic

Research does not determine whether an individual will respond similarly to the group patterns observed in trials. The overall certainty remains low for long-term use and the characteristics of adding Orphenadrine to the NSAID component in the patient experience. A significant research limitation is that the results apply only to the populations studied, and available evidence does not provide sufficient data to characterize outcomes in groups like older adults or those with complex health profiles.

Key Studies & References

Orphenadrine Citrate Extended-Release Tablets (DailyMed Drug Information)

Frequently Asked Questions (FAQ)

Common questions about Orcigesic (FAQ)

Q: Is Orcigesic a narcotic, opioid, or controlled substance?

A: Official documents classify the components of Orcigesic based on their mechanism of action. Mefenamic Acid is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and Orphenadrine is classified as a skeletal muscle relaxant. Regulatory classifications indicate that neither component is categorized as a narcotic or opioid drug.

Q: What conditions, besides its primary indication, is Orcigesic sometimes discussed for?

A: While the primary purpose is for pain and muscle spasm relief, official regulatory summaries for the Mefenamic Acid component indicate that it has also been evaluated in clinical trials for the treatment of Primary Dysmenorrhea. Primary dysmenorrhea refers to common menstrual pain and cramping.

Q: Does Orcigesic cause headaches or migraines as a side effect?

A: Yes, official documentation lists headache as a documented adverse reaction associated with the components of Orcigesic.

Q: What should a person watch for that might be a sign of a serious allergic reaction to Orcigesic?

A: Regulatory documents note the potential for severe adverse reactions, including Anaphylaxis and severe skin reactions. Signs of such serious events can include swelling of the face, tongue, or throat, difficulty breathing, and severe skin rashes or blistering. These signs are recognized as serious and warrant urgent attention.

Q: Can Orcigesic cause problems with liver or kidney function?

A: The Mefenamic Acid component, like other NSAIDs, carries warnings about the potential for serious renal (kidney) adverse events and the possibility of liver problems. This may involve changes in liver enzyme levels or a decline in kidney function. Use is contraindicated for patients with severe liver or kidney failure, according to regulatory information.

Q: Can Orcigesic affect mood or cause feelings of anxiety or depression?

A: Official adverse reaction profiles for the drug's components include infrequent reports of mood-related changes. These documented effects include excitement, confusion, discouragement, and feeling sad or empty.

Q: What common OTC medications are known to interact with Orcigesic?

A: Official documents advise caution or avoidance when combining Orcigesic with other medications, specifically naming Aspirin and other systemic NSAIDs. These are frequently available over the counter and can increase the risk of gastrointestinal issues when combined with Orcigesic.

Q: Is it safe to consume caffeine while taking Orcigesic?

A: Regulatory information for combination products related to Orcigesic and general drug interaction knowledge indicates that caffeine may enhance the effects of certain components. Official caution suggests that caffeine may enhance the effects of certain components.

Q: Is Orcigesic described in official sources as an effective treatment?

A: Official regulatory bodies approve the use of Orcigesic for specific conditions, known as indications, only after reviewing evidence of clinical benefit derived from trials. This process means the medicine has been determined to produce a desired effect for its approved use.

Q: Why do doctors prescribe Orcigesic instead of other pain medications?

A: The unique characteristic of Orcigesic is its combination of two active ingredients. Official product descriptions define its general purpose as providing combined pain relief (via the NSAID component) and muscle relaxation (via the muscle relaxant component) in a single preparation, targeting both components of musculoskeletal discomfort.

Q: Can Orcigesic affect a person's sleep patterns?

A: Yes, official side effect information for the muscle relaxant component includes drowsiness as a common reaction. Less commonly, effects such as excitement or trouble sleeping have also been reported, which may impact sleep patterns.

Q: Does Orcigesic typically cause changes in appetite or weight?

A: Adverse reaction reports associated with the Mefenamic Acid component include changes to appetite (such as loss of appetite). In rare instances, unusual weight gain or loss, have also been documented in official regulatory reports.

Q: Is hair loss listed as a possible side effect of Orcigesic in official documents?

A: Official documentation does list hair loss or thinning of the hair as a less common or rare adverse reaction associated with the Mefenamic Acid component of Orcigesic.

Q: Is there a known risk of dependence or withdrawal symptoms with Orcigesic?

A: Regulatory information for the Orphenadrine component notes the potential for physical dependence and the development of tolerance with repeated use.

Q: Can Orcigesic interfere with other treatments for chronic conditions?

A: Yes, official documents cite potential interactions with prescription medications used to treat various chronic conditions. These include drugs for high blood pressure (such as ACE inhibitors and beta-blockers) and certain medications for diabetes (sulfonylurea drugs).

Q: How quickly can a person expect Orcigesic to start relieving symptoms?

A: Official product monographs for the Orphenadrine component state that the onset of action following a single oral dose has been demonstrated within one hour. However, individual response times may vary.

Q: What is the typical duration of effect for a dose of Orcigesic?

A: The controlled-release formulation of the Orphenadrine component is officially noted to remain active throughout a 12-hour dosing interval.

Q: Is Orcigesic available as a lower-cost generic medication?

A: The individual active components of Orcigesic, Mefenamic Acid and Orphenadrine, are widely available as generic medications in many regulated markets. The availability of a generic version of the specific combination product may vary by region.

Q: Where can the public find summaries of the clinical research on Orcigesic?

A: Authoritative information regarding the clinical research is primarily summarized in the official prescribing information and public-facing documents provided by government drug regulatory agencies, such as the FDA or EMA.

Q: Does Orcigesic have a 'Black Box' warning from the FDA or equivalent agency?

A: The Mefenamic Acid component is part of the NSAID drug class, which is subject to the FDA's Boxed Warning (often called a 'Black Box' warning). This warning highlights the potential for serious cardiovascular thrombotic events (like heart attack or stroke) and severe gastrointestinal events.

Q: What is the difference between an adverse event and a side effect, as described for Orcigesic?

A: Regulatory definitions generally distinguish an adverse event as any undesirable experience during treatment, regardless of whether it was caused by the medicine. A side effect, however, is typically an effect that has been confirmed in studies to be directly caused by the medicine.

Q: What information is publicly available about the safety profile of Orcigesic?

A: Official information regarding the safety profile, including contraindications, serious risks, and all documented adverse reactions, is publicly available. This information is mandated to be contained within the prescribing information and drug information databases maintained by government drug regulatory agencies.

How should Orcigesic be stored and disposed of?

How to Store and Dispose of Orcigesic?

Orcigesic tablets must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). The medication must be protected from light and moisture by remaining in its original container, which must be kept tightly closed.

Storage and Disposal Requirements

Storage Classification	Regulatory Requirement
Temperature Range	Controlled Room Temperature: 20 C to 25 C
Protection	Protect from moisture and light; avoid excessive heat.
Container Rule	Keep in original, tightly closed container.
Child Safety	Keep out of the reach of children.

Official disposal guidance mandates that any unused or expired tablets should be managed through an approved drug take-back program. If a program is unavailable, certain high-risk medications, as determined by regulatory agencies, must be flushed down the toilet immediately to prevent accidental access.

Orcigesic